"Abrocitinib induction, randomized withdrawal, and retreatment in patie" by Andrew Blauvelt, Jonathan I. Silverberg et al.
 

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Document Type

Journal Article

Publication Date

1-1-2021

Journal

Journal of the American Academy of Dermatology

DOI

10.1016/j.jaad.2021.05.075

Keywords

abrocitinib; atopic dermatitis; JADE REGIMEN; JAK1 inhibitor; response; treatment

Abstract

Background: The heterogeneous course of moderate-to-severe atopic dermatitis necessitates treatment flexibility. Objective: We evaluated the maintenance of abrocitinib-induced response with continuous abrocitinib treatment, dose reduction or withdrawal, and response to treatment reintroduction following flare (JAK1 Atopic Dermatitis Efficacy and Safety [JADE] REGIMEN: National Clinical Trial 03627767). Methods: Patients with moderate-to-severe atopic dermatitis responding to open-label abrocitinib 200 mg monotherapy for 12 weeks were randomly assigned in a 1:1:1 ratio to blinded abrocitinib (200 or 100 mg) or placebo for 40 weeks. Patients experiencing flare received rescue treatment (abrocitinib 200 mg plus topical therapy). Results: Of 1233 patients, 798 responders to induction (64.7%) were randomly assigned. The flare probability during maintenance was 18.9%, 42.6%, and 80.9% with abrocitinib 200 mg, abrocitinib 100 mg, and placebo, respectively. Among patients with flare in the abrocitinib 200 mg, abrocitinib 100 mg, and placebo groups, 36.6%, 58.8%, and 81.6% regained investigator global assessment 0/1 response, respectively, and 55.0%, 74.5%, and 91.8% regained eczema area and severity index response, respectively, with rescue treatment. During maintenance, 63.2% and 54.0% of patients receiving abrocitinib 200 and 100 mg, respectively, experienced adverse events. Limitations: The definition of protocol-defined flare was not established, limiting the generalizability of findings. Conclusion: Induction treatment with abrocitinib was effective; most responders continuing abrocitinib did not flare. Rescue treatment with abrocitinib plus topical therapy effectively recaptured response.

Link to Full Text

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 100
    • Policy Citations: 4
  • Usage
    • Abstract Views: 8
  • Captures
    • Readers: 104
  • Mentions
    • News Mentions: 5
  • Social Media
    • Shares, Likes & Comments: 2
see details

Share

COinS